Edition:
United Kingdom

Smith & Nephew PLC (SN.L)

SN.L on London Stock Exchange

1,503.50GBp
22 Mar 2019
Change (% chg)

-26.50 (-1.73%)
Prev Close
1,530.00
Open
1,526.00
Day's High
1,532.00
Day's Low
1,495.00
Volume
1,569,603
Avg. Vol
2,399,787
52-wk High
1,548.50
52-wk Low
1,242.50

Chart for

About

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip... (more)

Overall

Beta: 0.84
Market Cap(Mil.): £12,228.70
Shares Outstanding(Mil.): 874.88
Dividend: 9.50
Yield (%): --

Financials

  SN.L Industry Sector
P/E (TTM): 18.66 32.18 32.54
EPS (TTM): 0.75 -- --
ROI: 13.97 13.74 13.82
ROE: 21.29 16.44 15.24

Deals of the day-Mergers and acquisitions

March 12 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

12 Mar 2019

Smith & Nephew to buy Osiris in regenerative products push

Smith & Nephew Plc said on Tuesday it would buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million (500.4 million pounds), as the British medical products maker looks to bulk up in an area that is quickly growing.

12 Mar 2019

Britain's Smith & Nephew to buy Osiris in regenerative products push

Smith & Nephew Plc said on Tuesday it would buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million, as the British medical products maker looks to bulk up in an area that is quickly growing.

12 Mar 2019

UPDATE 1-Britain's Smith & Nephew to buy Osiris in regenerative products push

March 12 Smith & Nephew Plc said on Tuesday it would buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million, as the British medical products maker looks to bulk up in an area that is quickly growing.

12 Mar 2019

Smith & Nephew to buy Osiris Therapeutics for $660 mln

March 12 British medical products maker Smith & Nephew Plc said on Tuesday it would buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million, as it looks to boost profit margins and find new sources of growth.

12 Mar 2019

Smith & Nephew in talks to buy NuVasive for over $3 billion - FT

Britain's Smith & Nephew Plc has held talks to buy U.S. medical equipment maker NuVasive in a deal that would be worth more than $3 billion (£2.3 billion), the Financial Times reported on Friday, citing people familiar with the talks.

09 Feb 2019

Smith & Nephew in talks to buy NuVasive for over $3 billion: FT

Britain's Smith & Nephew Plc has held talks to buy U.S. medical equipment maker NuVasive in a deal that would be worth more than $3 billion, the Financial Times reported on Friday, citing people familiar with the talks.

09 Feb 2019

UPDATE 2-Smith & Nephew in talks to buy NuVasive for over $3 bln - FT

Feb 8 Britain's Smith & Nephew Plc has held talks to buy U.S. medical equipment maker NuVasive in a deal that would be worth more than $3 billion, the Financial Times reported on Friday, citing people familiar with the talks.

09 Feb 2019

UPDATE 1-Smith & Nephew in talks to buy NuVasive for over $3 bln - FT

Feb 8 Britain's Smith & Nephew Plc has held talks to buy U.S.-based medical equipment maker NuVasive in a deal that would be worth more than $3 billion, the Financial Times reported on Friday, citing people familiar with the talks.

08 Feb 2019

Smith & Nephew in talks to buy NuVasive for over $3 bln - FT

Feb 8 Britain's Smith & Nephew Plc has held talks to buy U.S.-based medical equipment maker NuVasive in a deal that would be worth more than $3 billion, the Financial Times reported on Friday, citing people familiar with the talks.

08 Feb 2019

Earnings vs. Estimates